Interventional Psychiatry

University of Virginia Health System researchers in Charlottesville, Va., found preliminary evidence that low-intensity focused ultrasound and vagus nerve stimulation could help reduce drug and alcohol cravings for individuals with substance use disorder.  Researchers at the UVA Center for Neuromodulation…

President Donald Trump said the University of Miami has given the federal government its original 1994 ibogaine Investigational New Drug application. The application will give “everyone direct access to the foundational FDA authorization to accelerate its development as a medical…

The Food and Drug Administration released guidance in July outlining recommendations for sponsors developing psychedelic drugs for the treatment of medical conditions, including psychiatric disorders and substance use disorders. The guidance addresses chemistry, manufacturing, nonclinical testing, abuse potential and clinical…

Compass Pathways reported that 39% of patients in the 25 milligrams arm of a phase 3 trial for highly chronic treatment-resistant depression achieved a clinically meaningful response after two doses of its synthetic, proprietary formulation of psilocybin and maintained that…

Ketamine clinics have grown from fewer than 100 nationwide in 2015 to more than 1,500 by 2024, part of a market estimated at roughly $3.4 billion to $3.8 billion.  The drug is a dissociative anesthetic that distorts perceptions of sight…

Health systems are investing in interventional psychiatry programs as demand for treatment-resistant depression therapies rises and payer policies evolve.  In 2021, an estimated 8.9 million U.S. adults were treated for major depressive disorder each year, and about 2.8 million —…